Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$119.99
$119.23
$99.74
$120.05
$4.72B0.47148,695 shs390,921 shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$60.03
-2.3%
$60.73
$38.88
$66.00
$7.42B1.321.44 million shs1.14 million shs
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
$52.48
$52.44
$12.21
$52.53
$6.25B1.711.94 million shsN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$37.71
-1.6%
$39.34
$30.73
$60.90
$2.25B2.34979,593 shs1.18 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00%0.00%0.00%0.00%0.00%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
+0.99%+5.12%-3.75%+8.86%+61.21%
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-3.43%+1.86%-2.39%-25.07%+22.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
3.995 of 5 stars
1.31.00.04.42.02.54.4
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
3.619 of 5 stars
3.41.00.04.43.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00
N/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.60
Moderate Buy$62.894.76% Upside
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
0.00
N/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$52.8040.02% Upside

Current Analyst Ratings Breakdown

Latest HALO, MNTA, CBPO, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
4/21/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$55.00 ➝ $58.00
4/10/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$58.00 ➝ $45.00
3/28/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$50.00
3/6/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
2/20/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
2/19/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$70.00 ➝ $72.00
2/4/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
2/4/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
2/4/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderweight ➝ Underweight$35.00 ➝ $40.00
2/4/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$54.00 ➝ $62.00
(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$503.70M9.38$5.01 per share23.93$45.09 per share2.66
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.02B7.30$4.86 per share12.35$2.95 per share20.35
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
$23.87M261.69N/AN/A$4.59 per share11.43
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$330.19M6.81N/AN/A$7.64 per share4.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$138.81M$4.2833.5227.90N/A27.43%8.32%7.64%N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$281.59M$3.4317.509.650.4243.74%157.78%25.34%5/6/2025 (Estimated)
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
-$290.05M-$3.03N/AN/AN/A-757.61%-61.44%-45.28%N/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.38N/AN/AN/A-59.76%-32.69%-25.25%5/5/2025 (Estimated)

Latest HALO, MNTA, CBPO, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.98N/AN/AN/A$231.21 millionN/A
5/5/2025Q2 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.56N/AN/AN/A$92.00 millionN/A
2/18/2025Q4 2024
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.17$1.19+$0.02$1.06$285.74 million$298.01 million
2/3/2025Q1 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.62-$0.53+$0.09-$0.53$86.96 million$88.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/A
12.01
10.13
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.14
7.80
9.15
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
N/A
6.38
6.38
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62

Institutional Ownership

CompanyInstitutional Ownership
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
34.77%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
N/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
2,26939.36 millionN/AOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390123.53 million120.20 millionOptionable
Momenta Pharmaceuticals, Inc. stock logo
MNTA
Momenta Pharmaceuticals
131119.03 millionN/AOptionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.65 million57.86 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

China Biologic Products stock logo

China Biologic Products NASDAQ:CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$60.03 -1.39 (-2.26%)
Closing price 04:00 PM Eastern
Extended Trading
$59.88 -0.15 (-0.24%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Momenta Pharmaceuticals stock logo

Momenta Pharmaceuticals NASDAQ:MNTA

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$37.71 -0.61 (-1.59%)
Closing price 04:00 PM Eastern
Extended Trading
$37.38 -0.33 (-0.88%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.